Table 1.
Demographic and clinical evaluation from the two participant groups.
| Variables | PD | HC | p-Value |
|---|---|---|---|
| N | 35 | 31 | |
| Sex (M/F) | 24/11 | 21/10 | 0.94 |
| Age (years) | 61.8 ± 8.5 | 58.1 ± 11.3 | 0.17 |
| Disease duration (years) | 5.9 ± 3.9 | n/a | – |
| CES-D | 15.7 ± 8.7 | n/a | – |
| Laterality score (− = left worse, + = right worse) | −2.45 ± 10.7 | n/a | – |
| Left worse/right worse (individual) | 22/13 | ||
| MDS-UPDRS | |||
| Part II | 21.8 ± 7.7 | n/a | – |
| Part III (OFF) | 30.0 ± 11.1 | n/a | – |
| Dopamine replacement therapy | |||
| Total LEDD (mg/day) | 632.7 ± 418.7 | n/a | – |
| Agonist single dose equivalent (mg/day) | 103.9 ± 71.6 | n/a | – |
Data are shown as mean ± standard deviation.
MDS-UPDRS Part III conducted off medication (36 h for DAgonist and 16 for LDOPA).
PD: Parkinson's Disease.
AMNART: American version of the National Adult Reading Test.
CES-D: Center for Epidemiologic Studies Depression Scale.
MDS-UPDRS: Movement Disorders Society-United Parkinsons Disease Rating Scale.
BIS: Barratt Impulsivity Scale.
LEDD: Levodopa Daily Dose.